Efficacy of Wen-Luo-Tong on Peripheral Neuropathy Induced by Chemotherapy or Target Therapy: A Randomized,Double-Blinded, Placebo-Controlled Trial

Bo DENG; Li-qun JIA; Dong-gui WAN; Bao-yi WANG; Zhi-qiang CHENG; Chao DENG

doi:10.1007/s11655-022-3575-y

Your Location：

Home >

Browse articles >

Efficacy of Wen-Luo-Tong on Peripheral Neuropathy Induced by Chemotherapy or Target Therapy: A Randomized,Double-Blinded, Placebo-Controlled Trial

Original Article | Updated：2022-06-27

- Efficacy of Wen-Luo-Tong on Peripheral Neuropathy Induced by Chemotherapy or Target Therapy: A Randomized,Double-Blinded, Placebo-Controlled Trial
- Chinese Journal of Integrative Medicine Vol. 28, Issue 7, Pages: 579-585(2022)
- Affiliations：
  
  1.Center of Science and Technology, China-Japan Friendship Hospital, Beijing (100029), China
  2.Integrative Oncology Department of Chinese Medicine and Western Medicine, China-Japan Friendship Hospital, Beijing (100029), China
- Author bio：
  
  Prof. JIA Li-qun, E-mail: liqun-jia@hotmail.com
- Funds：
- DOI：10.1007/s11655-022-3575-y
  CLC：
- Published：01 July 2022，
  
  Published Online：18 May 2022，
  
  Accepted：13 October 2021
Scan for full text
Bo DENG, Li-qun JIA, Dong-gui WAN, et al. Efficacy of Wen-Luo-Tong on Peripheral Neuropathy Induced by Chemotherapy or Target Therapy: A Randomized,Double-Blinded, Placebo-Controlled Trial. [J]. Chinese Journal of Integrative Medicine 28(7):579-585(2022)
DOI：

Bo DENG, Li-qun JIA, Dong-gui WAN, et al. Efficacy of Wen-Luo-Tong on Peripheral Neuropathy Induced by Chemotherapy or Target Therapy: A Randomized,Double-Blinded, Placebo-Controlled Trial. [J]. Chinese Journal of Integrative Medicine 28(7):579-585(2022) DOI： 10.1007/s11655-022-3575-y.

摘要

目的:

评价温络通 (WLT) 外用颗粒治疗化疗或靶向治疗所致周围神经病变 (PN) 的疗效.

方法:

本研究为随机、双盲、安慰剂对照试验. 2019年7月至2020年1月

收集中日友好医院就诊的化疗或靶向治疗所致周围神经病变患者共78例

随机分为温络通组 (39例) 及对照组 (39例)

分别给予WLT (浸泡手足) 或安慰剂治疗1周

两组均给与给予甲钴胺神经营养治疗. 主要终点是国家癌症研究所不良事件共同毒性标准 (NCI-CTCAE) 评估的PN等级. 次要终点包括客观评价指标触觉阈值和主观评价指标神经病变症状、周围神经病变生活质量调查问卷 (QLQ-CIPN20) 和生活质量调查问卷核心版 (QLQ-C30) 评估的患者生活质量.

结果:

治疗后WLT组NCI评分下降程度明显优于对照组 (1.00±0.29 vs 1.75±0.68

0.01) ; WLT组总有效率82.05%

明显高于对照组 (51.28%

0.01) . 与对照组相比

WLT组指尖阈值和神经病变症状评分下降程度明显优于对照组. 与对照组相比

WLT组生活质量QLQ-cipn20评分 (感觉神经、运动神经、自主神经和总分) 和QLQ-C30 (躯体领域、角色领域、情绪领域和整体健康) 均显著改善

明显优于对照组 (

0.01或

0.05) .

结论:

WLT外用可有效药治疗化疗或靶向治疗所致周围神经病变.

Abstract

Objective:

To evaluate the efficacy of Wen-Luo-Tong Granules (WLT) local administration in the treatment of patients with peripheral neuropathy (PN) induced by chemotherapy or target therapy.

Methods:

This study is a randomized

double-blinded

and placebo-controlled trial. Seventy-eight patients with PN induced by chemotherapy or target therapy were enrolled from China-Japan Friendship Hospital between July 2019 and January 2020. They were randomly assigned to WLT (39 cases) and control groups (39 cases) using a block randomization method. The WLT group received WLT (hand and foot bath) plus oral Mecobalamin for 1 week

while the control group received placebo plus oral Mecobalamin. The primary endpoint was PN grade evaluated by the National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE). The secondary endpoints included quantitative touch-detection threshold

neuropathy symptoms

Quality of Life Questionnaire- Chemotherapy Induced Peripheral Neuropathy (QLQ-CIPN20)

and Quality of Life Questionnaire-Core30 (QLQ-C30).

Results:

After treatment

the PN grade in the WLT group was significantly lower than that in the control group (1.00±0.29 vs. 1.75±0.68

0.01). The total effective rate in the WLT group was significantly higher than that in the control group (82.05% vs. 51.28%

0.01). Compared with the control group

the touchdetection thresholds at fingertips

neuropathy symptom score

QLQ-CIPN 20 (sensory scale

motor scale

autonomic scale

and sum score)

and QLQ-C30 (physical functioning

role functioning

emotional functioning

and global health) in the WLT group significantly improved after treatment (

0.01 or

0.05).

Conclusion:

WLT local administration was significantly effective in the treatment of patients with PN induced by chemotherapy or target therapy. (Trial registration No. ChiCTR1900023862)

关键词

Keywords

peripheral neuropathychemotherapytarget therapyChinese medicineWen-Luo-Tongrandomized controlled trial

references

Selvy M, Pereira B, Kerckhove N, Busserolles J, Farsi F,Guastella V, et al. Prevention, diagnosis and management of chemotherapy-induced peripheral neuropathy: a cross-sectional study of French oncologists' professional practices. Support Care Cancer 2021;29:4033-4043.

Salat K. Chemotherapy-induced peripheral neuropathy:part 1-current state of knowledge and perspectives for pharmacotherapy. Pharmacol Rep 2020;72:486-507.

Jordan B, Jahn F, Sauer S, Jordan K. Prevention and management of chemotherapy-induced polyneuropathy.Breast Care (Basel) 2019;14:79-84.

Tofthagen CS, Cheville AL, Loprinzi CL. The physical consequences of chemotherapy-induced peripheral neuropathy. Curr Oncol Rep 2020;22:50.

Cavaletti G, Marmiroli P. Pharmacotherapy options for managing chemotherapy-induced peripheral neurotoxicity.Expert Opin Pharmacother 2018;19:113-121.

Gordon-Williams R, Farquhar-Smith P. Recent advances in understanding chemotherapy-induced peripheral neuropathy. F1000Res 2020;9:F1000

Oveissi V, Ram M, Bahramsoltani R, Ebrahimi F, Rahimi R, Naseri R, et al. Medicinal plants and their isolated phytochemicals for the management of chemotherapy-induced neuropathy: therapeutic targets and clinical perspective. Daru 2019;27:389-406.

Wu BY, Liu CT, Su YL, Chen SY, Chen YH, Tsai MY. A review of complementary therapies with medicinal plants for chemotherapy-induced peripheral neuropathy. Complement Ther Med 2019;42:226-232.

Lin HM, Lin LF, Sun MY, Liu J, Wu Q. Topical delivery of four neuroprotective ingredients by Ethosome-Gel: synergistic combination for treatment of oxaliplatin-induced peripheral neuropathy. Int J Nanomed 2020;15:3251-3266.

Wu FZ, Xu WJ, Deng B, Liu SD, Deng C, Wu MY,et al. Wen-Luo-Tong Decoction attenuates paclitaxel-induced peripheral neuropathy by regulating linoleic acid and glycerophospholipid metabolism pathways. Front Pharmacol 2018;9:956.

Lin HM, Lin LF, Xia ZZ, Mao Y, Liu J, Xu LY, et al.Neuroprotective effects and UPLC-Q-TOF/MS-based active components identification of external applied a novel Wen-Luo-Tong microemulsion. Artif Cells Nanomed Biotechnol 2018;46:1981-1991.

Lin H, Michniak-Kohn B, Xia Z, Xu L, Kang Q, Chen C,et al. Transdermal delivery of compounds with different lipophilicity and molecular weight from W/O microemulsions analyzed by UPLC-QTOF/MS and LC-MS/MS. Curr Drug Deliv 2018;15:1009-1019.

Deng B, Jia L, Pan L, Song AP, Wang YY, Tan HY, et al.Wen-Luo-Tong prevents glial activation and nociceptive sensitization in a rat model of oxaliplatin-induced neuropathic pain. Evid Based Complement Alternat Med 2016;2016:3629489.

Le-Rademacher J, Kanwar R, Seisler D, Pachman DR,Qin R, Abyzov A, et al. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials. Support Care Cancer 2017;25:3537-3544.

Neeman E, Gresham G, Ovasapians N, Hendifar A, Tuli R, Figlin R, et al. Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ratings as predictors of clinical outcomes in patients with cancer. Oncologist 2019;24:e1460-e1466.

Li XQ, Sun YH, Zhang MK, Zhang BB, Wang XL. Clinical observation of mecobalamin in the treatment of peripheral neuropathy caused by chemotherapy with oxaliplatin. J Contempor Clin Med (Chin) 2018;31:3873,3825.

Bang H, Ni L, Davis CE. Assessment of blinding in clinical trials. Control Clin Trials 2004;25:143-156.

Hsieh YL, Chou LW, Hong SF, Chang FC, Tseng SW, Huang CC, et al. Laser acupuncture attenuates oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: a pilot prospective cohort study.Acupunct Med 2016;34:398-405.

Deng B, Jia L, Tan H, Yao X, Gao FY, Pan L, et al. Effects of Sangu Decoction on osteoclast activity in a rat model of breast cancer bone metastasis. Evid Based Complement Alternat Med 2012;2012:380419.

Kleckner IR, Kamen C, Gewandter JS, Mohile NA,Heckler CE, Culakova E, et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.Support Care Cancer 2018;26:1019-1028.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.J Natl Cancer Inst 1993;85:365-376.

Park SB, Alberti P, Kolb NA, Gewandter JS, Schenone A, Argyriou AA. Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 2019;24(Suppl 2):S13-S25.

Quintão NLM, Santin JR, Stoeberl LC, Corrêa TP, Melato J, Costa R. Pharmacological treatment of chemotherapy-induced neuropathic pain: PPARγ agonists as a promising tool. Front Neurosci 2019;13:907.

Zhi WI, Baser RE, Kwon A, Chen C, Li SQ, Piulson L,et al. Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing. Breast Cancer Res Treat 2021;186:761-768.

Saito T, Makiura D, Inoue J, Doi H, Yakushijin K, Okamura A, et al. Comparison between quantitative and subjective assessments of chemotherapy-induced peripheral neuropathy in cancer patients: a prospective cohort study.Phys Ther Res 2020;23:166-171.

Shimizuguchi T, Sekiya N, Hara K, Taguchi A, Nakajima Y,Miyake Y, et al. Radiation therapy and the risk of herpes zoster in patients with cancer. Cancer 2020;126:3552-3559.

Lee PY, Lai JN, Chiu LT, Wei YT. Incidence and time trends of herpes zoster among patients with head and neck cancer who did and did not undergo radiotherapy: a population-based cohort study. PLoS One 2021;16:e0250724.

Shin DH, Song KH. Increased risk of herpes zoster in gynecological cancer patients receiving radiotherapy combined with chemotherapy: a need for paying attention to vaccines. J Gynecol Oncol 2021;32:e35.

Wang X, Ding S. The biological and pharmacological connections between diabetes and various types of cancer.Pathol Res Pract 2021;227:153641.

Lazic A, Popović J, Paunesku T, Woloschak GE,Stevanović M. Insights into platinum-induced peripheral neuropathy-current perspective. Neural Regen Res 2020;15:1623-1630.

Ma LT, Bai Y, Li J, Qiao Y, Liu Y, Zheng J. Elemene Emulsion Injection administration reduces neuropathic pain by inhibiting astrocytic NDRG2 expression within spinal dorsal horn. Chin J Integr Med 2021;27:912-918.

Bonomo R, Cavaletti G. Clinical and biochemical markers in CIPN: a reappraisal. Rev Neurol (Paris) 2021;177:890-907.

Yamamoto S, Egashira N. Drug repositioning for the prevention and treatment of chemotherapy-induced peripheral neuropathy: a mechanism- and screening-based strategy. Front Pharmacol 2021;11:607780.

Wang AB, Housley SN, Flores AM, Kircher SM, Perreault EJ, Cope TC. A review of movement disorders in chemotherapy-induced neurotoxicity. J Neuroeng Rehabil 2021;18:16.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Effect and Safety of Herbal Medicine Foot Baths in Patients with Diabetic Peripheral Neuropathy: A Multicenter Double-Blind Randomized Controlled Trial

Reyanning Mixture on Asymptomatic or Mild SARS-CoV-2 Infection in Children and Adolescents:A Randomized Controlled Trial

Efficacy of Biejiajian Pill on Intestinal Microbiota in Patients with Hepatitis B Cirrhosis/Liver Fibrosis:A Randomized Double-Blind Controlled Trial

Effects of Bushen Yiqi Huoxue Decoction in Treatment of Patients with Diminished Ovarian Reserve:A Randomized Controlled Trial

Related Author

No data

Related Institution

Department of Endocrinology, Guangdong Provincial Hospital of Chinese Medicine

The Second Clinical College of Guangzhou University of Chinese Medicine

Department of Endocrinology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

Guangdong Provincial Academy of Chinese Medical Sciences

Department of Endocrinology, The First Affiliated Hospital of Henan University of Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰